Pharmacologic Targeting of Bacterial β-Glucuronidase Alleviates Nonsteroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice
- 10 February 2012
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 341 (2), 447-454
- https://doi.org/10.1124/jpet.111.191122
Abstract
Small intestinal mucosal injury is a frequent adverse effect caused by nonsteroidal anti-inflammatory drugs (NSAIDs). The underlying mechanisms are not completely understood, but topical (luminal) effects have been implicated. Many carboxylic acid-containing NSAIDs, including diclofenac (DCF), are metabolized to acyl glucuronides (AGs), and/or ether glucuronides after ring hydroxylation, and exported into the biliary tree. In the gut, these conjugates are cleaved by bacterial β-glucuronidase, releasing the potentially harmful aglycone. We first confirmed that DCF-AG was an excellent substrate for purified Escherichia coli β-d-glucuronidase. Using a previously characterized novel bacteria-specific β-glucuronidase inhibitor (Inhibitor-1), we then found that the enzymatic hydrolysis of DCF-AG in vitro was inhibited concentration dependently (IC50 ∼164 nM). We next hypothesized that pharmacologic inhibition of bacterial β-glucuronidase would reduce exposure of enterocytes to the aglycone and, as a result, alleviate enteropathy. C57BL/6J mice were administered an ulcerogenic dose of DCF (60 mg/kg i.p.) with or without oral pretreatment with Inhibitor-1 (10 μg per mouse, b.i.d.). Whereas DCF alone caused the formation of numerous large ulcers in the distal parts of the small intestine and increased (2-fold) the intestinal permeability to fluorescein isothiocyanate-dextran, Inhibitor-1 cotreatment significantly alleviated mucosal injury and reduced all parameters of enteropathy. Pharmacokinetic profiling of DCF plasma levels in mice revealed that Inhibitor-1 coadministration did not significantly alter the Cmax, half-life, or area under the plasma concentration versus time curve of DCF. Thus, highly selective pharmacologic targeting of luminal bacterial β-d-glucuronidase by a novel class of small-molecule inhibitors protects against DCF-induced enteropathy without altering systemic drug exposure.Keywords
This publication has 37 references indexed in Scilit:
- Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing DysbiosisGastroenterology, 2011
- Diclofenac metabolism in the mouse: Novelin vivometabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometryXenobiotica, 2011
- Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial EnzymeScience, 2010
- Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and PreventionGastroenterology Clinics of North America, 2010
- Pharmacologic Targeting or Genetic Deletion of Mitochondrial Cyclophilin D Protects from NSAID-Induced Small Intestinal Ulceration in MiceToxicological Sciences, 2010
- Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathyThe Esophagus, 2009
- Effect of the β-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferasesJournal of Pharmacy and Pharmacology, 2008
- NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?Gut, 2008
- Nonsteroidal antiinflammatory drugs and the small intestineCurrent Opinion in HIV and AIDS, 2007
- Rearrangement of diflunisal acyl glucuronide into its β-glucuronidase-resistant isomers facilitates transport through the small intestine to the colon of the ratLife Sciences, 2001